Meeting
2017 ASCO Annual Meeting
Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC).
Authors
Vivek Subbiah
The University of Texas MD Anderson Cancer Center, Houston, TX
Vivek Subbiah , Robert J. Kreitman , Zev A. Wainberg , Jae Yong Cho , Jan H.M. Schellens , Jean-Charles Soria , Patrick Y. Wen , Christoph Zielinski , Gladys Urbanowitz , Bijoyesh Mookerjee , Dazhe Wang , Fatima A. Rangwala , Bhumsuk Keam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Other Head and Neck Cancer (Salivary, Thyroid)
Clinical Trial Registration Number
NCT02034110
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6023)
DOI
10.1200/JCO.2017.35.15_suppl.6023
Abstract #
6023
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.
First Author: Gregory J. Riely
Poster
2021 ASCO Annual Meeting
Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.
First Author: Juergen Wolf
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz